Late-breaking phase 2 immunoPRISM trial data show teclistamab superior to Len/Dex in high-risk smoldering myeloma, with higher CR rates and PFS.
Omar Nadeem, MD
Advertisement
Omar Nadeem, MD, is clinical director of the Myeloma Immune Effector Cell Therapies Program at Dana-Farber Cancer Institute.
Articles by Omar Nadeem, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5